Urinary Cancer Risk Test 'MySignal®︎' Begins Sales at 224 'Kusuri no Lady' Stores

Craif Inc. (Location: Bunkyo-ku, Tokyo; CEO: Ryuichi Onoz, hereinafter Craif), a bio-AI startup, has begun offering its urinary cancer risk test 'MySignal' at 224 'Kusuri no Lady' stores, which are pharmacy and drugstores operated by Lady Pharmacy Co., Ltd. (Headquarters: Matsuyama City, Ehime Prefecture; President and CEO: Kazuo Fujita).

The 'MySignal Scan' and 'MySignal Light' will be sold at 'Kusuri no Lady' store counters. Additionally, the 'Kusuri no Lady Heart Shop,' an online store operated by Lady Pharmacy Co., Ltd., will carry all four products in the 'MySignal' series, catering to a wider range of needs.

By creating an environment where the 'MySignal Series' can be easily purchased, it is expected to lower the hurdles for cancer screening, such as 'not knowing,' 'too far,' or 'no time,' and lead to increased awareness for early consultation and early detection.

Craif will continue to provide opportunities for early cancer detection to more people through its expansion into pharmacies and drugstores.

■ List of Products Handled

At 'Kusuri no Lady' store counters:

'MySignal Scan'

'MySignal Light'

Kusuri no Lady Heart Shop (EC Shop):

'MySignal Scan'

'MySignal Light'

'MySignal Navi'

'MySignal Check'

■ Number of Stores Handling Products

224 'Kusuri no Lady' stores (primarily in the Shikoku and Chugoku regions)

List of Stores Handling Products

■ About the 'MySignal Series'

'MySignal Series' is a cancer risk test that leads to prevention and early detection. This series includes 'MySignal Scan,' a test that evaluates the risk of 10 types of cancer, including pancreatic cancer, with high accuracy using microRNA x AI; 'MySignal Light,' a test for evaluating cancer risk more easily; 'MySignal Navi,' a gene test specialized for cancer; and 'MySignal Check,' a test for monitoring and preventing DNA damage.

All tests can be performed without burdening the body, simply by collecting urine or saliva. Through these four tests, individuals can learn about their constitutional risk and support the prevention of onset by monitoring daily DNA damage. The aim is comprehensive cancer countermeasures that support early detection of cancers that cannot be prevented, thereby promoting cancer prevention and early detection.

For details, please visit the website.

https://misignal.jp/

The MySignal series is not a medical device. It determines risk by statistically calculating analyzed information and is not a substitute for a 'diagnosis' of cancer as a medical act. Even if the risk is determined to be low, it does not guarantee the absence of cancer or that cancer will not occur in the future.

■ About Craif

Craif is a bio-AI startup founded in 2018, dedicated to the early detection of cancer. By fusing its proprietary analysis technology platform 'NANO IP®︎ (NANO Intelligence Platform),' which detects various biomarkers such as DNA and microRNA from bodily fluids including urine with high precision, with AI technology, the company develops innovative tests that enable ultra-early cancer detection, treatment, and recovery. By widely delivering the power of biotechnology and AI to society, Craif promotes its vision of 'realizing a society where people live out their natural lifespans.'

【Company Profile】

Company Name: Craif Inc.

Representative: Ryuichi Onoz, Representative Director

Established: May 2018

Capital: 100 million yen (as of April 1, 2025)

Business: Research and development of next-generation tests for early detection of diseases, primarily in the cancer field, and for the realization of personalized medicine; provision of the urinary cancer risk test 'MySignal®︎'.

Headquarters: THE PORTAL iidabashi B1F, 8-30 Shinkawa-cho, Shinjuku-ku, Tokyo

URL: https://craif.com/